<DOC>
	<DOCNO>NCT00643916</DOCNO>
	<brief_summary>The purpose clinical trial describe safety immunogenicity one two dos Menactra® ( TetraMenD ) administer child less 2 year age . Primary Objective : To describe immunogenicity profile one two dos Menactra® ( TetraMenD ) administer subject age 9 , 12 , 15 , 18 month comparison immunogenicity one dose Menomune® administer child age 3 year &lt; 6 year age .</brief_summary>
	<brief_title>Study Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine Toddlers 9 18 Months Age</brief_title>
	<detailed_description>This Phase II , open-label , parallel , exploratory , multi-center study healthy toddler .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged either 9 , 12 , 15 18 month age 3 &lt; 6 year age day inclusion . Informed consent form approve site 's Institutional Review Board ( IRB ) sign parent legal guardian Able attend schedule visit comply trial procedure Exclusion Criteria : History serious chronic disease could interfere trial conduct completion . Known suspected impairment immunologic function . Acute medical illness without fever within last 72 hour , rectal temperature ≥ 100.4°F ( ≥ 38.0°C ) axillary temperature ≥ 99.4°F ( ≥ 37.4°C ) day inclusion . History invasive meningococcal disease ( confirm either clinically , serologically microbiologically ) previous meningococcal vaccination . Administration immune globulin blood product within 3 month , oral parenteral corticosteroid immunosuppressive therapy within last 6 week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial long receive one course within last two week prior enrollment . Antibiotic therapy within 72 hour prior blood sample drawn . Received schedule receive vaccine 28day period prior receipt either dose study vaccine , schedule receive vaccination influenza vaccination hyposensitization therapy 28day period receipt either dose study vaccine . Hyposensitization therapy influenza vaccination may receive two week receive trial vaccine . Suspected known hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . Thrombocytopenia bleed disorder contraindicate intramuscular vaccination Unable attend one schedule visit comply study procedure . Participation another clinical trial 4 week precede enrollment . Planned participation another clinical trial present trial period . Any condition , opinion investigator , would pose health risk subject interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Meningitis ; Meningococcal Infection</keyword>
</DOC>